MARKET

KYTX

KYTX

Kyverna Therapeutics
NASDAQ
8.44
+0.24
+2.93%
After Hours: 8.44 0 0.00% 18:02 06/26 EDT
OPEN
8.12
PREV CLOSE
8.20
HIGH
8.54
LOW
8.05
VOLUME
6.76M
TURNOVER
--
52 WEEK HIGH
13.67
52 WEEK LOW
2.520
MARKET CAP
513.11M
P/E (TTM)
-2.5737
1D
5D
1M
3M
1Y
5Y
1D
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Seeking Alpha · 2d ago
Kyverna appoints Ritesh Srivastava as chief legal and compliance officer
PUBT · 6d ago
Press Release: Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Dow Jones · 6d ago
Weekly Report: what happened at KYTX last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at KYTX last week (0608-0612)?
Weekly Report · 06/15 09:47
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
The Motley Fool · 06/08 18:54
Weekly Report: what happened at KYTX last week (0601-0605)?
Weekly Report · 06/08 09:44
Health Rounds: CAR-T therapy brings hope to kidney patients with few transplant options
Reuters · 06/04 19:53
More
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Webull offers Kyverna Therapeutics Inc stock information, including NASDAQ: KYTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYTX stock methods without spending real money on the virtual paper trading platform.